• Tue. Oct 26th, 2021

AstraZeneca, Ema evaluates Guillain-Barré syndrome cases after dose

Byeditorial

May 7, 2021

It is an immune system disorder that causes inflammation of the nerves and can cause pain, numbness, muscle weakness and difficulty walking. (Gbs) reported after administration of the anti-Covid vaccine Vaxzevria. This was reported by the EMA, in the report in which it takes stock of the last meeting of the Prac. Gbs, reminds the EU regulatory body, is a disorder of the immune system that causes inflammation of the nerves and can cause pain, numbness, muscle weakness and difficulty in walking. Read also The experts of the committee, explains the EMA, are analyzing “the data provided by the holder of the marketing authorization”, Aic, of the Anglo-Swedish vaccine “on the cases of Guillain-Barré syndrome reported following the vaccination. GBS was identified during the Aic process as a possible adverse event that requires specific monitoring activities “, the agency specifies. “The Prac – he underlines – has asked the holder of the marketing authorization to provide further detailed data, including an analysis of all reported cases, as part of the next safety report”. The committee will continue its review and provide further communications as new information becomes available.